Document |
Document Title |
WO/2001/012196A1 |
Compounds represented by formula (I) wherein each of Y, X and R individually is H, OH, alkyl, alkoxy, aryl, halo, CF¿3? and NO¿2?, provided that at least one of Y, X and R is other than H; and pharmaceutically acceptable salts thereof ...
|
WO/2001/008661A2 |
A solid, oral, controlled release dosage form comprising a therapeutically effective amount of an opioid compound, or a salt thereof, a matrix-forming polymer and an ionic exchange resin.
|
WO/2001/005795A1 |
Remedies or preventives for frequent urination or urinary incontinence which contain as the active ingredient a quinolinomorphinan derivative represented by formula (6) or pharmacologically acceptable acid addition salt thereof.
|
WO/2000/078763A2 |
Novel chemical analogs are disclosed for the essential heroin metabolite 6-O-acetyl morphine (6MAM). The analogs optionally can be made to contain protein reactive groups, and can be used to form protein conjugates, fluorescently labeled...
|
WO/2000/076506A1 |
The present invention relates to a pharmaceutical formulation for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0. Such formulations provide enhanced absorptio...
|
WO2000056735B1 |
The present invention pertains to a process for the preparation of the 10-keto analogs of morphinan compounds. In the case of compounds having a 3-hydroxyl group, the 3-methyl ether protected analog is synthesized by selective phenolic m...
|
WO/2000/066588A1 |
The present invention provides a method of preparing a 14-hydroxy opioid of Formula (II): which includes reacting the correponding 14-H opioid (possessing a hydrogen at the C-14 position) with a cobalt (III) oxidant which can oxidize the...
|
WO/1999/067231A1 |
Nitric acid salts with medicines having an antihypertensive activity.
|
WO/1999/064430A2 |
The invention provides a novel method for synthesising M6G, and intermediates therefor. In order to synthesise M6G the major problem to overcome is to obtain the glycoside linkage with very high $g(b)-selectivity since prior methods prod...
|
WO/1999/038869A1 |
This invention relates to novel structural analogues and derivatives of compounds with general analgesic or related pharmacological activity. In particular the invention relates to derivatives of opioid compounds, particularly morphine a...
|
WO/1999/015528A1 |
The invention relates to a material consisting of the acidic addition salt of a morphine alkaloid and an organic acid. The organic acid is selected from: monoesters of C¿3?-C¿16? dicarboxylic acids with monovalent C¿1?-C¿4? alcohols;...
|
WO/1999/011289A1 |
Remedies for drug addiction which contain as the active ingredient $g(k)-opioid receptor agonists typified by the compounds represented by general formula (I). These $g(k)-opioid receptor agonists are useful as remedies for drug addictio...
|
WO/1999/005146A1 |
Hyponatremia remedies containing as the active ingredient opioid $g(k) receptor agonists represented by general formula (I) or the like; and a method of treatment therewith. The agonists exhibit both the property as a hydragogue diuretic...
|
WO/1999/002529A1 |
The invention provides processes for the conversion of normorphinone and its derivatives, which can be synthesized from morphine, to the corresponding 14-hydroxynormorphinone and its derivatives including oxycodone, oxymorphone, noroxymo...
|
WO/1999/002158A1 |
Stable medicinal compositions characterized by containing 4,5-epoxymorphinane derivatives and at least one member selected from among water-soluble antioxidants, fat-soluble antioxidants, synergists, saccharides and surfactants.
|
WO/1998/057637A1 |
The present invention encompasses methods for treating chronic fatigue syndrome and fibromyalgia by administering buprenorphine or a salt thereof. The compound may optionally be administered in a pharmaceutical composition. Preferred com...
|
WO/1998/043977A1 |
Quinolinomorphinane derivatives represented by the following general formula (I) or pharmacologically acceptable acid addition salts thereof and remedies and preventives for brain disorders containing the same. In said formula, R?1� re...
|
WO/1998/043978A1 |
Novel morphinane derivatives having an agonistic or antagonistic activity as a compound capable of binding to opioid $g(e)-receptors and pharmacologically acceptable salts thereof. These derivatives are represented by general formula (I).
|
WO/1998/031684A1 |
Indolomorphinane derivatives represented by general formula (I) or pharmacologically acceptable acid-addition salts thereof, and remedies/preventives for cerebral disorders containing the same, wherein R?1� represents cyclopropylmethyl...
|
WO/1998/023290A1 |
An antipruritic agent comprising as the active ingredient an opioid $g(k) receptor agonist useful for the treatment of pruritus in various diseases accompanied by pruritus, and novel morphinane quaternary ammonium salt derivatives and mo...
|
WO/1998/022467A1 |
A process for the preparation of 14-alkoxyindolomorphinans and 14-alkoxybenzofuranomorphinans is disclosed. The process facilitates the preparation of a large variety of 14-alkoxy substituted indolomorphinans and benzofuranomorphinans in...
|
WO/1998/005667A1 |
A novel process for preparing narcotic analgesics such as hydrocodone and hydromorphone using catalytic amounts of homogeneous organometallic complexes is disclosed.
|
WO/1998/002033A1 |
There is disclosed an improved poppy straw of a stably reproducing Papaver somniferum for the extraction of thebaine and/or oripavine, the threshed straw having thebaine and oripavine constituting about 50 % by weight or greater of the a...
|
WO/1997/044317A2 |
The present invention provides a method for N-deprotecting an opioid compound, a method for N-deprotecting and O-demethylating an opioid compound, a method for O-demethylating an opioid compound, and a method for O-demethylating a nonpep...
|
WO/1997/035585A1 |
The present invention provides a method for providing anesthesia using a composition comprising olanzapine and one or more opioids.
|
WO/1997/031918A1 |
The invention concerns morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type, preferably the morphine and diamorphine salts of diclofenac (formula 1). The invention further concerns a p...
|
WO/1997/029109A1 |
This invention concerns compounds of formula (I), including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydroge...
|
WO/1997/025331A1 |
Substituted mono heterocycle-condensed morphinoid derivatives of formula (I) are potent and selective, delta opioid agonists and antagonists, and are of use as analgesics and for treating pathological conditions which, customarily, can b...
|
WO/1997/022606A1 |
Morphine derivatives of formula (I), process for preparing them and their use as analgesics.
|
WO/1997/019083A1 |
A process for extracting morphine from opium is described. In the process, opium is extracted with a basic alcoholic solution. The basic alcoholic solution is filtered and the alcohol removed from the filtrate to leave a residue. The res...
|
WO/1997/019082A1 |
The specification describes a methylation resin comprising methyl(dialkyl)anilinium salts or methyl(diaryl)anilinium salts covalently bonded to the resin. The methylation resin is used in the solid-phase synthesis of codeine from morphin...
|
WO/1997/017344A1 |
There are provided novel compounds of formula (I), wherein X, R1, R2, R3, R4 and R5 are as defined in the specification and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for ...
|
WO/1996/028450A1 |
Disclosed are morphine-3-esters, the enzymatic hydrolysis of which has a half-life of from 0.5 to 12 hours under physiologic conditions and the non-enzymatic hydrolysis of which has a half-life in excess of 24 hours in an aqueous medium ...
|
WO/1996/028451A1 |
Disclosed are morphine-3-esters of formula (I), the enzymatic hydrolysis of which has a half-life of from 0.5 to 12 hours under physiologic conditions and the non-enzymatic hydrolysis of which has a half-life in excess of 24 hours in an ...
|
WO/1996/027375A2 |
Urinary incontenence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and/or pharmaceutically acceptable salts, alone or in combination wi...
|
WO/1996/023793A1 |
Compounds are provided of formula (1), wherein R1 is (C1-C5)alkyl, C3-C6(cycloalkyl)alkyl, C5-C7(cycloalkenyl)alkyl, (C6-C12)aryl, (C6-C12)aralkyl, trans(C4-C5)alkenyl, allyl or furan-2-ylalkyl, R2 is H, OH or O2C(C1-C5)alkyl; R3 is H, (...
|
WO/1996/022303A1 |
The present invention relates to a range of therapeutic compounds conjugated to one to three acyl groups derived from fatty acids. The therapeutic compounds are selected from the following group: 1) the corticosterone family of drugs; 2)...
|
WO/1996/016063A1 |
A compound of formula (I) wherein R1 = H (morphine analogue), CH3 (codeine analogue), R2 = H, alkyl group of 1 to 4 carbon atoms, allyl, cyclopropylmethyl, R3 = a group (A), -O-CH2-R4 (ether), -O-COCH = CHR4 (cinnamate), R4 = (B), wherei...
|
WO/1996/004247A1 |
The present invention provides a process for making a compound having a structure according to formula (I) wherein A1, A2 and A3 are independently carbon or nitrogen and R1, R3, R4 and R6 are known quinolone substituents; and wherein one...
|
WO/1996/002545A1 |
Compounds of formula (I), are selective delta opioid agonists and antagonists, and are useful as analgesics and in treating general neurologic disorders.
|
WO/1995/032973A1 |
A process is described for the synthesis of nalbuphine. The process results in a product having very low levels of the undesirable 'beta'-epimer. The process is a five-step synthesis that begins with a compound such as an N,03-bis(alkoxy...
|
WO/1995/031463A1 |
New morphinane derivatives of formula (I), their pharmaceutically acceptable salts, a process for their preparation and their use in the manufacture of pharmaceutical preparations.
|
WO/1995/031464A1 |
New morphinane derivatives of formula (I), their pharmaceutically acceptable salts, a process for their preparation and their use in therapy.
|
WO/1995/018186A1 |
The design and synthesis of novel aminimide-derived molecular modules and the use of the modules in the construction of new molecules and fabricated materials is disclosed. The new molecules and fabricated materials are molecular recogni...
|
WO/1995/004058A1 |
A 2-(3-benzoylphenyl)propionic acid codeine salt, a preparation method therefor and pharmaceutical compositions containing said salt for use in painkillers.
|
WO/1995/003308A1 |
A morphinan derivative represented by formula (1) or a pharmacologically acceptable acid-addition salt thereof, and analgesic, diuretic, antitussive and brain cell protective agents each containing the derivative or the salt as the activ...
|
WO/1995/003307A1 |
A novel brain cell protective containing a morphinane derivative represented by the compound of formula (1) or a pharmacologically acceptable acid-addition salt thereof as the active ingredient. This compound exhibits an excellent protec...
|
WO/1995/000518A1 |
A novel morphinan derivative represented by general formula (I), which is useful as an analgesic free from the problem of habituation and toxicity and is highly physiologically active. In said formula (I) R1 represents C1-C4 alkyl, allyl...
|
WO/1994/014445A1 |
An antitussive containing a delta-opioid antagonist or a pharmacologically acceptable salt thereof as the active ingredient. It has a potent activity, does not give side effects such as impaired mentation, and can be administered perorally.
|
WO/1994/007896A1 |
An indole derivative represented by general formula (I) and a pharmacologically acceptable acid addition salt thereof, wherein R1 represents alkyl, cycloalkyl, etc.; R2 represents hydrogen, hydroxy, alkanoyloxy or alkoxy; R3 represents h...
|